



## Archit Organosys Limited

25/9/A & B, Phase III, G.I.D.C. Naroda,  
Ahmedabad-382330, Gujarat, INDIA.

Phone : +91-79-40082447

CIN : L24110GJ1993PLC019941

Date: 14/08/2023

To,  
**BSE Limited**  
Phiroze Jeejeebhoy Tower,  
Dalal Street,  
Mumbai – 400 001.

Dear Sir/Madam,

**Sub.: Outcome of Board Meeting.**

**Ref: Security ID: ARCHITORG; Security Code: 524640**

With reference to the above, we would like to inform that the Board of Directors of the Company at their meeting held today i.e. on Monday, 14<sup>th</sup> August, 2023 have considered and approved the following:

1. The unaudited Standalone and Consolidated financial results of the Company for the quarter ended on 30<sup>th</sup> June, 2023.

Board has reviewed the Limited Review Report in the prescribed format from Statutory Auditors on unaudited Standalone and Consolidated Financial Results of the Company for the quarter ended on 30<sup>th</sup> June, 2023.

The Unaudited Standalone and Consolidated Financial Result and Limited Review Reports of the Statutory Auditor for the aforesaid quarter are attached herewith.

The Board Meeting commenced at 3.00 P.M. and concluded at 4.25 P.M.

Kindly take the same on your records.

Yours faithfully,  
**For Archit Organosys Limited**

**Vijay Boliya**  
**Company Secretary & Compliance Officer**

Encl.: As above



**ARCHIT ORGANOSYS LIMITED**  
 Reg Office: Plot No. 25/9-A Phase-III GIDC, Naroda, Ahmedabad -382330  
 Website: www.architorg.com email: share@architorg.com  
 Tele: +91-79-22821154 CIN: L24110GJ1993PLC019941

**Statement of un-audited Financial Result (Standalone) for the quarter ended on June 30, 2023 (Rs. In Lacs)**

No.	Particulars	For the Quarter ended			For the Year ended
		June 30, 2023	March 31, 2023	June 30, 2022	March 31, 2023
		Un-audited	Audited (Refer note 4)	Un-audited	Audited
<b>I</b>	<b>Income</b>				
[a]	Revenue From Operations	3 099.98	4 654.84	3 035.18	12 778.29
[b]	Other Income	70.62	135.00	20.96	192.37
<b>II</b>	<b>Total Income (a+ b)</b>	<b>3 170.60</b>	<b>4 789.84</b>	<b>3 056.13</b>	<b>12 970.66</b>
<b>III</b>	<b>Expenses:</b>				
[a]	Cost of materials consumed	804.70	862.36	1 139.47	3 923.85
[b]	Purchase of Stock in Trade	1 265.31	2 390.61	383.24	3 720.47
[c]	Changes in inventories of finished goods, work in progress and stock in - trade	( 51.12)	307.55	( 5.30)	65.02
[d]	Employees benefits expenses	190.88	194.87	175.60	736.72
[e]	Finance costs	52.49	50.67	86.05	220.91
[f]	Depreciation and amortisation expenses	119.31	116.10	119.62	483.14
[g]	Power & Fuel	127.21	124.45	149.54	555.14
[h]	Other expenses	437.88	483.12	475.31	1 886.79
<b>IV</b>	<b>Total Expenses</b>	<b>2 946.66</b>	<b>4 529.73</b>	<b>2 523.52</b>	<b>11 592.04</b>
<b>V</b>	<b>Profit/(Loss) before exceptional and extraordinary items and tax (II-IV)</b>	<b>223.94</b>	<b>260.11</b>	<b>532.61</b>	<b>1 378.62</b>
<b>VI</b>	<b>Exceptional Items</b>	0.00	0.00	0.00	( 164.96)
<b>VII</b>	<b>Profit before extraordinary items and tax (V-VI)</b>	<b>223.94</b>	<b>260.11</b>	<b>532.61</b>	<b>1 543.58</b>
<b>VIII</b>	<b>Extraordinary items</b>		0.00	0.00	0.00
<b>IX</b>	<b>Profit before tax (VII-VIII)</b>	<b>223.94</b>	<b>260.11</b>	<b>532.61</b>	<b>1 543.58</b>
<b>X</b>	<b>Tax Expenses:</b>				
(a)	Current Tax	58.00	50.00	102.00	265.00
(b)	Deferred Tax	2.24	43.95	120.46	268.99
(C)	MAT Cedit Entitlement	0.00	( 34.80)	( 102.00)	( 133.13)
	<b>Total Tax Expenses</b>	<b>60.24</b>	<b>59.15</b>	<b>120.46</b>	<b>400.86</b>
<b>XI</b>	<b>Profit(loss) for the Period from Continuing operations(IX-X)</b>	<b>163.70</b>	<b>200.96</b>	<b>412.15</b>	<b>1 142.72</b>
<b>XII</b>	<b>Profit(loss) for the Period from discontinuing operations</b>	0.00	0.00	0.00	0.00
<b>XIII</b>	<b>Tax expenses of discontinuing operations</b>	0.00	0.00	0.00	0.00
<b>XIV</b>	<b>Profit(loss) for the Period from discontinuing operations (after tax) (XII-XIII)</b>	0.00	0.00	0.00	0.00
<b>XV</b>	<b>Net Profit(loss) for the Period (XI-XIV)</b>	<b>163.70</b>	<b>200.96</b>	<b>412.15</b>	<b>1 142.72</b>
<b>XVI</b>	<b>Other Comprehensive Income</b>		0.00	0.00	0.00
[a]	Items that will not be reclassified to Profit or Loss (Net of Tax)	( 0.30)	7.30	0.00	7.30
[b]	Items that will be reclassified to Profit or Loss (Net of tax)	0.00	0.00	0.00	0.00
<b>XVII</b>	<b>Total Comprehensive income for the period (XV+XVI) (Comprising Profit/(Loss) and other Comprehensive income for the period)</b>	<b>163.40</b>	<b>208.26</b>	<b>412.15</b>	<b>1 150.02</b>
<b>XVIII</b>	<b>Paid-up equity share capital (face value of Rs.10)</b>	<b>2 052.07</b>	<b>2 052.07</b>	<b>2 052.07</b>	<b>2 052.07</b>
<b>XIX</b>	<b>Reserves / Other Equity</b>				<b>4 133.30</b>
<b>XX</b>	<b>Earning per equity Shares(before extra-ordinary Items)</b>				
[a]	Basic	0.80	0.98	2.01	5.57
[b]	Diluted	0.80	0.98	2.01	5.57
<b>XXI</b>	<b>Earning per equity Shares(after extra-ordinary Items)</b>				
[a]	Basic	0.80	0.98	2.01	5.57
[b]	Diluted	0.80	0.98	2.01	5.57

For and on behalf of the Board



*WALZ*

Date: 14/08/2023  
 Place: Ahmedabad

**Kandarp Amin**  
 Chairman and Whole-time Director  
 DIN:00038972

**Notes:**

- 1 The standalone financial results of the Company for the quarter ended June 30, 2023 have been reviewed and recommended by the Audit Committee and approved by the Board of Directors of the Company in their meeting held on August 14, 2023. The Standalone Results are being Published in accordance with Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
- 2 These Financial Results have been prepared in accordance with Indian Accounting Standards (Ind- AS) as prescribed under section 133 of Companies Act 2013 read with Rule 3 of the Companies (Indian Accounting Standards) Rules 2015 and relevant amendment thereafter.
- 3 During the quarter ended 30th June, 2023, the company has sold 81% stake in its only subsidiary "Archit Life Science Limited" (ALSL) for total consideration amounting to Rs. 8.10 lacs i.e. at basic value, pursuant to resolution passed by Board of Directors of the company dated 17th June, 2023.
- 4 The Figures for the quarter ended 31st March, 2023 are the balancing figures between the Audited Figures in respect of the Full Financial Year and published Year to date figures up to the third Quarter of the Financial Year 2022-23.
- 5 Segment Reporting as defined in Ind AS 108 is not applicable, since the Company operates in only one segment.
- 6 Comparative figures have been rearranged/regrouped wherever necessary.

**Date:** 14/08/2023  
**Place:** Ahmedabad



**For and on behalf of the Board**

*VAWH*

**Kandarp Amin**  
**Chairman and Whole-time Director**  
**DIN:00038972**

*G. K. Choksi & Co.*

*Chartered Accountants*

1201 - 901, North Tower, One42, Chhanalal Joshi Marg,  
Opp. Jayntilal Park BRTS, Off. Ambli BRTS Road, Ahmedabad 380 054.  
Dial : 91 - 79 - 6819 8900 - 901 : E-mail : info@gkcco.com

**Independent Auditor's Review Report on the Quarterly Unaudited Standalone Financial Results of the Company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended**

The Board of Directors,  
**ARCHIT ORGANOSYS LIMITED**  
Ahmedabad

1. We have reviewed the accompanying statement of standalone unaudited financial results of **ARCHIT ORGANOSYS LIMITED** for the quarter ended 30<sup>th</sup> June, 2023 being submitted by the company pursuant to requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015, as amended ('the Regulation'). This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial results based on our review.
2. The preparation of the statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standards 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 read with Rule 3 of Companies (Indian Accounting Standards) Rules, 2015, as amended and other accounting principles generally accepted in India, read with circular is the responsibility of the Company's management and has been approved by the Board of the Company. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of standalone unaudited financial results, prepared in accordance with applicable accounting standards and other recognized accounting practices and policies, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

**FOR G. K. CHOKSI & CO.**

[Firm Registration No. 101895W]  
*Chartered Accountants*

*3* 

**SANDIP A. PARIKH**

*Partner*

Mem. No. 40727

UDIN: 23040727BgUWEK8141

Place : Ahmedabad  
Date : 14<sup>th</sup> August, 2023



Branches : 708, Raheja Chambers, Free Press Journal Road, Nariman Point, Mumbai - 400 021.  
Dial : 91 - 22 - 6632 4446

514/515, Tolstoy House, Tolstoy Marg, Janpath, New Delhi - 110 001.  
Dial : 91 - 11 - 4371 7773 - 74

'Surya Bhavan', Station Road, Petlad - 388 450. Dial : 91 - 2697 - 224 108

Email : info@gkcco.com



**ARCHIT ORGANOSYS LIMITED**  
 Reg Office: Plot No. 25/9-A Phase-III GIDC, Naroda, Ahmedabad -382330  
 Website: www.architorg.com email: share@architorg.com  
 Tele: +91-79-22821154 CIN: L24110GJ1993PLC019941

**Statement of un-audited Financial Result (Consolidated) for the Quarter ended on June 30, 2023 (Rs. in Lacs)**

No.	Particulars	For the Quarter ended			For the Year ended
		June 30, 2023	March 31, 2023	June 30, 2022	March 31, 2023
		Un-audited	Audited (Refer note 4)	Unaudited (Refer note 5)	Audited
<b>I</b>	<b>Income</b>				
[a]	Revenue From Operations	3 099.98	4 654.84	3 035.18	12 778.29
[b]	Other Income	64.49	128.68	20.96	186.05
<b>II</b>	<b>Total Income (a+ b)</b>	<b>3 164.47</b>	<b>4 783.52</b>	<b>3 056.13</b>	<b>12 964.34</b>
<b>III</b>	<b>Expenses:</b>				
[a]	Cost of materials consumed	804.70	862.36	1 139.47	3 923.85
[b]	Purchase of Stock in Trade	1 265.31	2 390.61	383.24	3 720.47
[c]	Changes in inventories of finished goods, work in progress and stock in -trade	( 51.12)	307.55	( 5.30)	65.02
[d]	Employees benefits expenses	190.88	194.87	175.60	736.72
[e]	Finance costs	52.49	50.67	86.05	220.91
[f]	Depreciation and amortisation expenses	119.31	116.10	119.62	483.14
[g]	Power & Fuel	127.21	124.45	149.54	555.14
[h]	Other expenses	437.97	484.13	475.31	1 888.29
<b>IV</b>	<b>Total Expenses</b>	<b>2 946.75</b>	<b>4 530.74</b>	<b>2 523.52</b>	<b>11 593.54</b>
<b>V</b>	<b>Profit/(Loss) before exceptional and extraordinary items and tax (II-IV)</b>	<b>217.72</b>	<b>252.78</b>	<b>532.61</b>	<b>1 370.80</b>
<b>VI</b>	<b>Exceptional Items</b>	0.00	0.00	0.00	( 164.96)
<b>VII</b>	<b>Profit before extraordinary items and tax (V-VI)</b>	<b>217.72</b>	<b>252.78</b>	<b>532.61</b>	<b>1 535.76</b>
<b>VIII</b>	<b>Extraordinary items</b>	0.00	0.00	0.00	0.00
<b>IX</b>	<b>Profit before tax (VII-VIII)</b>	<b>217.72</b>	<b>252.78</b>	<b>532.61</b>	<b>1 535.76</b>
<b>X</b>	<b>Tax Expenses:</b>				
(a)	Current Tax	58.00	50.00	102.00	265.00
(b)	Deferred Tax	2.24	43.95	120.46	268.99
(C)	MAT Cedit Entitlement	0.00	( 34.80)	( 102.00)	( 133.13)
	<b>Total Tax Expenses</b>	<b>60.24</b>	<b>59.15</b>	<b>120.46</b>	<b>400.86</b>
<b>XI</b>	<b>Profit(loss) for the Period from Continuing operations(IX-X)</b>	<b>157.48</b>	<b>193.63</b>	<b>412.15</b>	<b>1 134.90</b>
<b>XII</b>	<b>Profit(loss) for the Period from discontinuing operations</b>	0.00	0.00	0.00	0.00
<b>XIII</b>	<b>Tax expenses of discontinuing operations</b>	0.00	0.00	0.00	0.00
<b>XIV</b>	<b>Profit(loss) for the Period from discontinuing operations (after tax) (XII-XIII)</b>	0.00	0.00	0.00	0.00
<b>XV</b>	<b>Net Profit(loss) for the Period (XI-XIV)</b>	<b>157.48</b>	<b>193.63</b>	<b>412.15</b>	<b>1 134.90</b>
<b>XVI</b>	<b>Other Comprehensive Income</b>				
[a]	Items that will not be reclassified to Profit or Loss (Net of Tax)	( 0.30)	7.30	0.00	7.30
[b]	Items that will be reclassified to Profit or Loss (Net of tax)	0.00	0.00	0.00	0.00
<b>XVII</b>	<b>Total Comprehensive income for the period (XV+XVI) (Comprising Profit/(Loss) and other Comprehensive income for the period)</b>	<b>157.18</b>	<b>200.93</b>	<b>412.15</b>	<b>1 142.20</b>
<b>XVIII</b>	<b>Paid-up equity share capital (face value of Rs.10)</b>	2 052.07	2 052.07	2 052.07	2 052.07
<b>XIX</b>	<b>Reserves / Other Equity</b>				4 125.48
<b>XX</b>	<b>Earning per equity Shares(before extra-ordinary Items)</b>				
[a]	Basic	0.77	0.94	2.01	5.53
[b]	Diluted	0.77	0.94	2.01	5.53
<b>XXI</b>	<b>Earning per equity Shares(after extra-ordinary Items)</b>				
[a]	Basic	0.77	0.94	2.01	5.53
[b]	Diluted	0.77	0.94	2.01	5.53

For and on behalf of the Board

  
 Kandarp Amin

Chairman and Whole-time Director  
 DIN:00038972

Date: 14/08/2023  
 Place: Ahmedabad



**Notes:**

- 1 The Consolidated Financial Results of the Company for the Quarter ended June 30, 2023 have been reviewed and recommended by the Audit Committee and approved by the Board of Directors of the Parent Company in their meeting held on August 14, 2023. The Consolidated Results are being Published in accordance with Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
- 2 These Financial Results have been prepared in accordance with Indian Accounting Standards (Ind- AS) as prescribed under section 133 of Companies Act 2013 read with Rule 3 of the Companies (Indian Accounting Standards) Rules 2015 and relevant amendment thereafter.
- 3 During the quarter ended 30th June, 2023, the parent company has sold 81% stake in its only subsidiary "Archit Life Science Limited" (ALSL) for total consideration amounting to Rs. 8.10 lacs i.e. at basic value, pursuant to resolution passed by Board of Directors of the parent company dated 17th June, 2023.
- 4 The Figures for the quarter ended 31st March, 2023 are the balancing figures between the Audited Figures in respect of the Full Financial Year and published Year to date figures up to the third Quarter of the Financial Year 2022-23.
- 5 The corresponding previous quarter figures are as per Standalone results of the reporting company as the subsidiary was incorporated after June 30, 2022 in the previous financial year.
- 6 Segment Reporting as defined in Ind AS 108 is not applicable, since the Company operates in only one segment.
- 7 Comparative figures have been rearranged/regrouped wherever necessary.

Date: 14/08/2023  
Place: Ahmedabad



For and on behalf of the Board

Kandarp Amin  
Chairman and Whole-time Director  
DIN:00038972



*G. K. Choksi & Co.*  
*Chartered Accountants*

1201 - 901, North Tower, One42, Chhantalal Joshi Marg,  
Opp. Jayntilal Park BRTS, Off. Ambli BRTS Road, Ahmedabad 380 054.  
Dial : 91 - 79 - 6819 8900 - 901 ; E-mail : info@gkcco.com

**Independent Auditor's Review Report on the Quarterly Unaudited Consolidated Financial Results of the Company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended**

The Board of Directors,  
**ARCHIT ORGANOSYS LIMITED**  
Ahmedabad

1. We have reviewed the accompanying statement of Consolidated unaudited financial results of **ARCHIT ORGANOSYS LIMITED** ("the Parent") and its subsidiary (the parent and subsidiary together known as "the Group") for the quarter ended 30<sup>th</sup> June, 2023 being submitted by the Parent pursuant to requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015, as amended ("the Regulation"). This statement is the responsibility of the Parent's Management and has been approved by the Parent's Board of Directors. Our responsibility is to issue a report on these financial results based on our review.
2. The preparation of the statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standards 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 read with Rule 3 of Companies (Indian Accounting Standards) Rules, 2015, as amended and other accounting principles generally accepted in India, read with circular is the responsibility of the Parent's management and has been approved by the Board of the Parent. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

4. The Statement includes the results of the following entities:

Name of the Company	Relation
Archit Organosys Limited	Parent
Archit Life Science Limited	Wholly owned subsidiary (upto 17 <sup>th</sup> June, 2023)

5. Based on our review conducted and procedures performed as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying statement of consolidated unaudited financial results, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

**FOR G. K. CHOKSI & CO.**

[Firm Registration No. 101895W]

*Chartered Accountants*

*3*

**SANDIP A. PARIKH**

*Partner*

Mem. No. 40727

UDIN: 23040727BGUWE11571



Place : Ahmedabad  
Date : 14<sup>th</sup> August, 2023

Branches : 708, Raheja Chambers, Free Press Journal Road, Nariman Point, Mumbai - 400 021.

Dial : 91 - 22 - 6632 4446

514/515, Tolstoy House, Tolstoy Marg, Janpath, New Delhi - 110 001.

Dial : 91 - 11 - 4371 7773 - 74

'Surya Bhavan', Station Road, Petlad - 388 450. Dial : 91 - 2697 - 224 108

Email : info@gkcco.com